N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Sponsor: Eli Lilly and Company • ClinicalTrials.gov ID: NCT07226843

Registry updated: 2026-10-06
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Interventions

  • LY4584180 (Drug)
    administered orally
  • Rituximab (Drug)
    administered through IV infusion

Eligibility criteria

Inclusion Criteria: * Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy: * Diffuse large B-cell lymphoma - not otherwise specified * High-grade B-cell lymphoma * Diffuse large B-cell lymphoma - transformed from indolent lymphomas * Follicular large B-cell lymphoma * Follicular lymphoma * Other non-Hodgkin lymphoma * Has measurable disease * Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy Exclusion Criteria: * Has an active second cancer * Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval. * Has known Cytomegalovirus infection. Participants with negative status are eligible * Has known hepatitis B or C infection or uncontrolled HIV * Has known significant heart disease

Conditions

Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Follicular Lymphoma

Locations

  • Mayo Clinic - Scottsdale — Scottsdale, Arizona, United States
  • City of Hope — Duarte, California, United States
  • University of California, Los Angeles (UCLA) - Medical Center — Los Angeles, California, United States
  • University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
  • Colorado Blood Cancer Institute — Denver, Colorado, United States
  • University of Miami - Sylvester Cancer Center — Miami, Florida, United States
  • Florida Cancer Specialists - Sarasota — Sarasota, Florida, United States
  • Emory University Hospital — Atlanta, Georgia, United States
  • Massachusetts General Hospital — Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute — Boston, Massachusetts, United States
  • Mayo Clinic - Rochester — Rochester, Minnesota, United States
  • Columbia University — New York, New York, United States
  • University of Rochester — Rochester, New York, United States
  • The Ohio State University (OSU) — Columbus, Ohio, United States
  • Oregon Health & Science University (OHSU) — Portland, Oregon, United States
  • Sarah Cannon Research Institute — Nashville, Tennessee, United States
  • Vanderbilt University Medical Center — Nashville, Tennessee, United States
  • Texas Oncology - DFW (Sammons CC) — Dallas, Texas, United States
  • Baylor College of Medicine — Houston, Texas, United States
  • University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance) — Seattle, Washington, United States
  • Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States
  • CHU de Nantes - Hotel-Dieu — Nantes, France
  • Institut Curie — Paris, France
  • CHU Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie — Pessac, France
  • HCL Centre Hospitalier Lyon Sud — Pierre-Bénite, France
  • Oncopole Claudius Regaud — Toulouse, France
  • Charite Universitaetsmedizin Berlin — Berlin, Germany
  • Universitaetsklinikum Koeln (AoeR) — Cologne, Germany
  • Universitaetsklinikum Essen — Essen, Germany
  • Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet — Frankfurt am Main, Germany
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola — Bologna, Italy
  • Istituto Europeo di Oncologia — Milan, Italy
  • National Cancer Center Hospital East — Chiba, Japan
  • Okayama University Hospital — Okayama, Japan
  • Cancer Institute Hospital of JFCR — Tokyo, Japan
  • Pratia Onkologia Katowice — Katowice, Poland
  • Pratia MCM Krakow — Krakow, Poland
  • AIDPORT Sp. z o.o. — Skorzewo, Poland
  • Instytut Hematologii i Transfuzjologii w Warszawie — Warsaw, Poland
  • Institut Catala d'Oncologia - L'Hospitalet — Barcelona, Spain
  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz — Madrid, Spain
  • King's College Hospital — London, United Kingdom
  • The Royal Marsden NHS Foundation Trust — London, United Kingdom
  • Nottingham City Hospital — Nottingham, United Kingdom
  • Derriford Hospital — Plymouth, United Kingdom
  • University Hospital Southampton NHS Foundation Trust — Southampton, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record